{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T18:46:14Z","timestamp":1790189174132,"version":"4.1.0"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100019266","name":"Korea Medical Device Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019266","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2019R1A6A1A11051471"],"award-info":[{"award-number":["2019R1A6A1A11051471"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003052","name":"Ministry of Trade, Industry and Energy","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003052","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003569","name":"Ministry of Food and Drug Safety","doi-asserted-by":"publisher","award":["RS-2020-KD000033"],"award-info":[{"award-number":["RS-2020-KD000033"]}],"id":[{"id":"10.13039\/501100003569","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003621","name":"Ministry of Science, ICT and Future Planning","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003621","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003625","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003625","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003662","name":"Korea Evaluation Institute of Industrial Technology","doi-asserted-by":"publisher","award":["KEIT 20018560"],"award-info":[{"award-number":["KEIT 20018560"]}],"id":[{"id":"10.13039\/501100003662","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003662","name":"Korea Evaluation Institute of Industrial Technology","doi-asserted-by":"publisher","award":["NTIS 1415184668"],"award-info":[{"award-number":["NTIS 1415184668"]}],"id":[{"id":"10.13039\/501100003662","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Biomaterialia"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.actbio.2023.09.025","type":"journal-article","created":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T12:20:54Z","timestamp":1695212454000},"page":"273-288","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["Intravitreal injectable hydrogel rods with long-acting bevacizumab delivery to the retina"],"prefix":"10.1016","volume":"171","author":[{"given":"Simin","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hye Kyoung","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Shin","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sae Im","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Yong","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3692-7169","authenticated-orcid":false,"given":"Se Joon","family":"Woo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4825-6609","authenticated-orcid":false,"given":"Ki Dong","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.actbio.2023.09.025_bib0001","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1016\/j.ophtha.2009.05.039","article-title":"Neovascular age-related macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumab","volume":"116","author":"Funk","year":"2009","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.actbio.2023.09.025_bib0002","doi-asserted-by":"crossref","first-page":"108","DOI":"10.3390\/pharmaceutics13010108","article-title":"Ocular drug delivery to the retina: current innovations and future perspectives","volume":"13","author":"Kim","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.actbio.2023.09.025_bib0003","series-title":"Optical Coherence Tomography Findings after an Intravitreal Injection of Bevacizumab (Avastin\u00ae) for Neovascular Age-Related Macular Degeneration","first-page":"331","author":"Rosenfeld","year":"2005"},{"issue":"3","key":"10.1016\/j.actbio.2023.09.025_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.ophtha.2005.11.019","article-title":"Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration","volume":"113","author":"Avery","year":"2006","journal-title":"Ophthalmology"},{"issue":"5","key":"10.1016\/j.actbio.2023.09.025_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajo.2010.11.017","article-title":"Pharmacotherapy for neovascular age-related macular degeneration: an analysis of the 100% 2008 medicare fee-for-service part B claims file","volume":"151","author":"Brechner","year":"2011","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.actbio.2023.09.025_bib0006","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/j.csbj.2019.09.004","article-title":"Recent advancements in non-invasive formulations for protein drug delivery","volume":"17","author":"Bajracharya","year":"2019","journal-title":"Comput. Struct. Biotechnol. J."},{"issue":"6","key":"10.1016\/j.actbio.2023.09.025_bib0007","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1177\/2042018813512360","article-title":"Anti-vascular endothelial growth factor therapy for diabetic macular edema","volume":"4","author":"Boyer","year":"2013","journal-title":"Ther. Adv. Endocrinol. Metab."},{"issue":"8","key":"10.1016\/j.actbio.2023.09.025_bib0008","article-title":"Anti-vascular endothelial growth factor for neovascular age-related macular degeneration","author":"Solomon","year":"2014","journal-title":"Cochrane Database System. Rev."},{"issue":"8","key":"10.1016\/j.actbio.2023.09.025_bib0009","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.ophtha.2019.03.036","article-title":"The port delivery system with ranibizumab for neovascular age-related macular degeneration: results from the randomized phase 2 ladder clinical trial","volume":"126","author":"Campochiaro","year":"2019","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1016\/j.actbio.2023.09.025_bib0010","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1038\/s41433-019-0479-y","article-title":"Ranibizumab port delivery system (RPDS): realising long awaited dream of prolonged VEGF suppression","volume":"34","author":"Sharma","year":"2020","journal-title":"Eye"},{"issue":"4","key":"10.1016\/j.actbio.2023.09.025_bib0011","doi-asserted-by":"crossref","first-page":"642","DOI":"10.3390\/polym13040642","article-title":"Nanoparticle-hydrogel composite drug delivery system for potential ocular applications","volume":"13","author":"Hsu","year":"2021","journal-title":"Polymers"},{"issue":"1","key":"10.1016\/j.actbio.2023.09.025_bib0012","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000055638","article-title":"Effect of particle size of polymeric nanospheres on intravitreal kinetics","volume":"33","author":"Sakurai","year":"2001","journal-title":"Ophthalmic Res."},{"issue":"8","key":"10.1016\/j.actbio.2023.09.025_bib0013","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1016\/j.drudis.2019.05.005","article-title":"Intravitreal nanoparticles for retinal delivery","volume":"24","author":"Huang","year":"2019","journal-title":"Drug Discov. Today"},{"issue":"11","key":"10.1016\/j.actbio.2023.09.025_bib0014","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1002\/jbm.a.36450","article-title":"Nanoceria-loaded injectable hydrogels for potential age-related macular degeneration treatment","volume":"106","author":"Wang","year":"2018","journal-title":"J. Biomedic. Mater. Res. Part A"},{"issue":"12","key":"10.1016\/j.actbio.2023.09.025_bib0015","doi-asserted-by":"crossref","first-page":"H41","DOI":"10.1002\/adma.201003963","article-title":"Hyaluronic acid hydrogels for biomedical applications","volume":"23","author":"Burdick","year":"2011","journal-title":"Adv. Mater."},{"issue":"4\u20135","key":"10.1016\/j.actbio.2023.09.025_bib0016","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.addr.2007.03.013","article-title":"Injectable matrices and scaffolds for drug delivery in tissue engineering","volume":"59","author":"Kretlow","year":"2007","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"12","key":"10.1016\/j.actbio.2023.09.025_bib0017","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1016\/j.biomaterials.2007.11.047","article-title":"Influence of the degree of methacrylation on hyaluronic acid hydrogels properties","volume":"29","author":"Bencherif","year":"2008","journal-title":"Biomaterials"},{"issue":"6","key":"10.1016\/j.actbio.2023.09.025_bib0018","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1016\/j.actbio.2009.02.030","article-title":"End-group effects on the properties of PEG-co-PGA hydrogels","volume":"5","author":"Bencherif","year":"2009","journal-title":"Acta Biomater."},{"issue":"3","key":"10.1016\/j.actbio.2023.09.025_bib0019","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.jacc.2004.04.040","article-title":"Injectable fibrin scaffold improves cell transplant survival, reduces infarct expansion, and induces neovasculature formation in ischemic myocardium","volume":"44","author":"Christman","year":"2004","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.actbio.2023.09.025_bib0020","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.addr.2012.09.012","article-title":"Thermosensitive sol\u2013gel reversible hydrogels","volume":"64","author":"Jeong","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"8","key":"10.1016\/j.actbio.2023.09.025_bib0021","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1039\/b713009k","article-title":"Injectable hydrogels as unique biomedical materials","volume":"37","author":"Yu","year":"2008","journal-title":"Chem. Soc. Rev."},{"issue":"1","key":"10.1016\/j.actbio.2023.09.025_bib0022","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1167\/iovs.13-13120","article-title":"Biocompatible reverse thermal gel sustains the release of intravitreal bevacizumab in vivo","volume":"55","author":"Rauck","year":"2014","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"2","key":"10.1016\/j.actbio.2023.09.025_bib0023","doi-asserted-by":"crossref","DOI":"10.1167\/tvst.4.2.5","article-title":"Injectable chemically crosslinked hydrogel for the controlled release of bevacizumab in vitreous: a 6-month in vivo study","volume":"4","author":"Yu","year":"2015","journal-title":"Transl. Vis. Sci. Technol."},{"issue":"9","key":"10.1016\/j.actbio.2023.09.025_bib0024","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.3109\/02713683.2015.1101140","article-title":"Controlled and extended in vitro release of bioactive anti-vascular endothelial growth factors from a microsphere-hydrogel drug delivery system","volume":"41","author":"Osswald","year":"2016","journal-title":"Curr. Eye Res."},{"issue":"9","key":"10.1016\/j.actbio.2023.09.025_bib0025","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1080\/02713683.2017.1302590","article-title":"In vivo efficacy of an injectable microsphere-hydrogel ocular drug delivery system","volume":"42","author":"Osswald","year":"2017","journal-title":"Curr. Eye Res."},{"key":"10.1016\/j.actbio.2023.09.025_bib0026","doi-asserted-by":"crossref","first-page":"228","DOI":"10.3389\/fbioe.2020.00228","article-title":"Hydrogel biomaterials for application in ocular drug delivery","volume":"8","author":"Lynch","year":"2020","journal-title":"Front. Bioeng. Biotechnol."},{"issue":"2","key":"10.1016\/j.actbio.2023.09.025_bib0027","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1039\/C1SM06513K","article-title":"Shear-thinning hydrogels for biomedical applications","volume":"8","author":"Guvendiren","year":"2012","journal-title":"Soft Matter"},{"issue":"48","key":"10.1016\/j.actbio.2023.09.025_bib0028","doi-asserted-by":"crossref","first-page":"19590","DOI":"10.1073\/pnas.1211516109","article-title":"Injectable preformed scaffolds with shape-memory properties","volume":"109","author":"Bencherif","year":"2012","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"35","key":"10.1016\/j.actbio.2023.09.025_bib0029","doi-asserted-by":"crossref","first-page":"13180","DOI":"10.1039\/c1jm12527c","article-title":"In situ cross-linkable gelatin\u2013poly (ethylene glycol)\u2013tyramine hydrogel via enzyme-mediated reaction for tissue regenerative medicine","volume":"21","author":"Park","year":"2011","journal-title":"J. Mater. Chem."},{"issue":"6","key":"10.1016\/j.actbio.2023.09.025_bib0030","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1021\/bm401787u","article-title":"Macro\/nano-gel composite as an injectable and bioactive bulking material for the treatment of urinary incontinence","volume":"15","author":"Park","year":"2014","journal-title":"Biomacromolecules"},{"issue":"91","key":"10.1016\/j.actbio.2023.09.025_bib0031","first-page":"e51312","article-title":"Endothelial cell tube formation assay for the in vitro study of angiogenesis","author":"DeCicco-Skinner","year":"2014","journal-title":"JoVE"},{"issue":"4","key":"10.1016\/j.actbio.2023.09.025_bib0032","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/nprot.2010.6","article-title":"In vitro angiogenesis: endothelial cell tube formation on gelled basement membrane extract","volume":"5","author":"Arnaoutova","year":"2010","journal-title":"Nat. Protoc."},{"issue":"4","key":"10.1016\/j.actbio.2023.09.025_bib0033","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1167\/tvst.9.4.7","article-title":"Intraocular pharmacokinetics of 10-fold intravitreal ranibizumab injection dose in rabbits","volume":"9","author":"Kim","year":"2020","journal-title":"Transl. Vis. Sci. Technol."},{"issue":"7","key":"10.1016\/j.actbio.2023.09.025_bib0034","doi-asserted-by":"crossref","first-page":"2914","DOI":"10.1021\/acs.biomac.2c00383","article-title":"Hyaluronic Acid-PEG-Based Diels\u2013Alder In Situ Forming Hydrogels for Sustained Intraocular Delivery of Bevacizumab","volume":"23","author":"Ilochonwu","year":"2022","journal-title":"Biomacromolecules"},{"issue":"6","key":"10.1016\/j.actbio.2023.09.025_bib0035","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1167\/tvst.9.6.20","article-title":"Intraocular distribution and kinetics of intravitreally injected antibodies and nanoparticles in rabbit eyes","volume":"9","author":"Kim","year":"2020","journal-title":"Transl. Vis. Sci. Technol."},{"key":"10.1016\/j.actbio.2023.09.025_bib0036","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1007\/s00417-014-2719-y","article-title":"Comparison of the efficacy of aflibercept, ranibizumab, and bevacizumab in an RPE\/choroid organ culture","volume":"252","author":"Klettner","year":"2014","journal-title":"Graefe's Arch. Clinic. Exp. Ophthalmol."},{"issue":"6","key":"10.1016\/j.actbio.2023.09.025_bib0037","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1167\/tvst.9.6.20","article-title":"Intraocular distribution and kinetics of intravitreally injected antibodies and nanoparticles in rabbit eyes","volume":"9","author":"Kim","year":"2020","journal-title":"Transl. Vis. Sci. Technol."},{"issue":"2","key":"10.1016\/j.actbio.2023.09.025_bib0038","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1089\/jop.2012.0138","article-title":"The vitreous humor as a barrier to nanoparticle distribution","volume":"29","author":"Mains","year":"2013","journal-title":"J. Ocular Pharmacol. Therap."},{"issue":"3","key":"10.1016\/j.actbio.2023.09.025_bib0039","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1002\/mabi.201500327","article-title":"Enhanced cellular activity in gelatin-poly (ethylene glycol) hydrogels without compromising gel stiffness","volume":"16","author":"Hoang Thi","year":"2016","journal-title":"Macromol. Biosci."},{"issue":"11","key":"10.1016\/j.actbio.2023.09.025_bib0040","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1002\/term.1917","article-title":"Horseradish peroxidase-catalysed in situ-forming hydrogels for tissue-engineering applications","volume":"9","author":"Bae","year":"2015","journal-title":"J. Tissue Eng. Regen. Med."},{"issue":"9","key":"10.1016\/j.actbio.2023.09.025_bib0041","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1177\/0885328219899787","article-title":"Horseradish peroxidase-catalyzed hydrogelation of fish gelatin with tunable mechanical properties and biocompatibility","volume":"34","author":"Thi","year":"2020","journal-title":"J. Biomater. Appl."},{"issue":"10","key":"10.1016\/j.actbio.2023.09.025_bib0042","doi-asserted-by":"crossref","first-page":"4523","DOI":"10.1167\/iovs.08-2055","article-title":"Comparison of bevacizumab, ranibizumab, and pegaptanib in vitro: efficiency and possible additional pathways","volume":"49","author":"Klettner","year":"2008","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"18","key":"10.1016\/j.actbio.2023.09.025_bib0043","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1039\/c3tb00578j","article-title":"In situ forming gelatin-based tissue adhesives and their phenolic content-driven properties","volume":"1","author":"Lee","year":"2013","journal-title":"J. Mater. Chem. B"},{"issue":"2\u20133","key":"10.1016\/j.actbio.2023.09.025_bib0044","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0168-3659(01)00248-6","article-title":"On the importance and mechanisms of burst release in matrix-controlled drug delivery systems","volume":"73","author":"Huang","year":"2001","journal-title":"J. Controlled Release"},{"key":"10.1016\/j.actbio.2023.09.025_bib0045","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.actbio.2020.09.015","article-title":"3D printing of drug-loaded multi-shell rods for local delivery of bevacizumab and dexamethasone: a synergetic therapy for retinal vascular diseases","volume":"116","author":"Won","year":"2020","journal-title":"Acta Biomater."},{"issue":"4","key":"10.1016\/j.actbio.2023.09.025_bib0046","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.3390\/pharmaceutics15041264","article-title":"Peptide nanofiber system for sustained delivery of anti-VEGF proteins to the eye vitreous","volume":"15","author":"Yaylaci","year":"2023","journal-title":"Pharmaceutics"},{"issue":"8","key":"10.1016\/j.actbio.2023.09.025_bib0047","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.freeradbiomed.2010.01.022","article-title":"Dynamics of H2O2 availability to ARPE-19 cultures in models of oxidative stress","volume":"48","author":"Kaczara","year":"2010","journal-title":"Free Rad. Biol. Med."},{"issue":"6","key":"10.1016\/j.actbio.2023.09.025_bib0048","first-page":"1941","article-title":"Controlled release bevacizumab in thermoresponsive hydrogel found to inhibit angiogenesis","volume":"24","author":"Hu","year":"2014","journal-title":"Biomed. Mater. Eng."},{"key":"10.1016\/j.actbio.2023.09.025_bib0049","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.carbon.2022.09.045","article-title":"Anti-angiogenic carbon nanovesicles loaded with bevacizumab for the treatment of age-related macular degeneration","volume":"201","author":"Anand","year":"2023","journal-title":"Carbon"},{"issue":"4","key":"10.1016\/j.actbio.2023.09.025_bib0050","first-page":"653","article-title":"Pharmacokinetics and distributions of bevacizumab by intravitreal injection of bevacizumab-PLGA microspheres in rabbits","volume":"8","author":"Ye","year":"2015","journal-title":"Int. J. Ophthalmol."},{"issue":"38","key":"10.1016\/j.actbio.2023.09.025_bib0051","doi-asserted-by":"crossref","first-page":"4002","DOI":"10.1039\/b706939a","article-title":"Novel approaches in microparticulate PLGA delivery systems encapsulating proteins","volume":"17","author":"Taluja","year":"2007","journal-title":"J. Mater. Chem."},{"issue":"10","key":"10.1016\/j.actbio.2023.09.025_bib0052","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1002\/jbm.a.35446","article-title":"Albuminated PLGA nanoparticles containing bevacizumab intended for ocular neovascularization treatment","volume":"103","author":"Varshochian","year":"2015","journal-title":"J. Biomedic. Mater. Res. Part A"},{"key":"10.1016\/j.actbio.2023.09.025_bib0053","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.jconrel.2020.01.036","article-title":"Injectable biodegradable bi-layered capsule for sustained delivery of bevacizumab in treating wet age-related macular degeneration","volume":"320","author":"Jiang","year":"2020","journal-title":"J. Controlled Release"},{"issue":"1","key":"10.1016\/j.actbio.2023.09.025_bib0054","doi-asserted-by":"crossref","DOI":"10.1167\/tvst.8.1.12","article-title":"Characterization of biodegradable microsphere-hydrogel ocular drug delivery system for controlled and extended release of ranibizumab","volume":"8","author":"Liu","year":"2019","journal-title":"Transl. Vis. Sci. Technol."},{"key":"10.1016\/j.actbio.2023.09.025_bib0055","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.jconrel.2022.10.036","article-title":"Six-month sustained delivery of anti-VEGF from in-situ forming hydrogel in the suprachoroidal space","volume":"352","author":"Jung","year":"2022","journal-title":"J. Controlled Release"},{"issue":"1","key":"10.1016\/j.actbio.2023.09.025_bib0056","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics13010108","article-title":"Ocular drug delivery to the retina: current innovations and future perspectives","volume":"13","author":"Kim","year":"2021","journal-title":"Pharmaceutics"},{"issue":"9","key":"10.1016\/j.actbio.2023.09.025_bib0057","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1517\/17425247.5.9.1039","article-title":"Iluvien\u2122: a new sustained delivery technology for posterior eye disease","volume":"5","author":"Kane","year":"2008","journal-title":"Expert Opin. Drug Deliv."},{"issue":"1","key":"10.1016\/j.actbio.2023.09.025_bib0058","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1080\/10717544.2022.2069301","article-title":"The Port Delivery System with ranibizumab: a new paradigm for long-acting retinal drug delivery","volume":"29","author":"Ranade","year":"2022","journal-title":"Drug Deliv."},{"issue":"5","key":"10.1016\/j.actbio.2023.09.025_bib0059","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1007\/s40123-022-00532-9","article-title":"Pharmacokinetics of the port delivery system with ranibizumab in the ladder phase 2 trial for neovascular age-related macular degeneration","volume":"11","author":"Wykoff","year":"2022","journal-title":"Ophthalmol. Ther."},{"issue":"3","key":"10.1016\/j.actbio.2023.09.025_bib0060","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.ophtha.2021.09.016","article-title":"Archway randomized phase 3 trial of the port delivery system with ranibizumab for neovascular age-related macular degeneration","volume":"129","author":"Holekamp","year":"2022","journal-title":"Ophthalmology"}],"container-title":["Acta Biomaterialia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1742706123005640?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1742706123005640?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T18:10:45Z","timestamp":1761675045000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1742706123005640"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":60,"alternative-id":["S1742706123005640"],"URL":"https:\/\/doi.org\/10.1016\/j.actbio.2023.09.025","relation":{},"ISSN":["1742-7061"],"issn-type":[{"value":"1742-7061","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intravitreal injectable hydrogel rods with long-acting bevacizumab delivery to the retina","name":"articletitle","label":"Article Title"},{"value":"Acta Biomaterialia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.actbio.2023.09.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}